-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Vhap2rj3o/x9MoHYpviH/AH0WA3r/9KZpr9uUpWnLGc7eh07UYO0K65iIb5QS0zK Z5GgdRvGYMYhLiYkcN0lyw== 0001209191-11-004090.txt : 20110120 0001209191-11-004090.hdr.sgml : 20110120 20110120111617 ACCESSION NUMBER: 0001209191-11-004090 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110118 FILED AS OF DATE: 20110120 DATE AS OF CHANGE: 20110120 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brege Laura CENTRAL INDEX KEY: 0001365619 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28298 FILM NUMBER: 11537777 MAIL ADDRESS: STREET 1: C/O ONYX PHARMACEUTICALS, INC. STREET 2: 2100 POWELL STREET CITY: EMERYVILLE STATE: CA ZIP: 94608 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ONYX PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001012140 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943154463 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2100 POWELL STREET CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 5105976500 MAIL ADDRESS: STREET 1: 2100 POWELL STREET CITY: EMERYVILLE STATE: CA ZIP: 94608 4 1 doc4.xml FORM 4 SUBMISSION X0303 4 2011-01-18 0 0001012140 ONYX PHARMACEUTICALS INC ONXX 0001365619 Brege Laura C/O ONYX PHARMACEUTICALS, INC. 2100 POWELL ST. EMERYVILLE CA 94608 0 1 0 0 EVP & Chief Operating Officer Common Stock 2011-01-18 4 M 0 12500 15.44 A 31427 D Common Stock 2011-01-18 4 S 0 12500 35.6383 D 18927 D Stock Option (Right to Buy) 15.44 2011-01-18 4 M 0 12500 0.00 D 2016-06-12 Common Stock 12500 62500 D Includes 413 shares purchased through the issuer's ESPP. Shares sold pursuant to a 10b5-1 plan. The shares were sold between $35.47 and $35.71. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Twenty-Five percent of the shares subject to the option become exercisable 1 year from the date of grant and the remainder become exercisable at a rate of 1/48th per month thereafter. /s/ Matthew K. Fust, Attorney-in-fact 2011-01-19 -----END PRIVACY-ENHANCED MESSAGE-----